Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.65 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 2/20 | 0.59 |
| ▸ | TCF4 | P15884 | 1/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31681318 | 0.87 | MAPK1 (0.70) | KMT2AMEN1POLBLIMK1LIMK2 | |
| SCHEMBL31681206 | 0.86 | TCF4 (0.76) | KMT2AMEN1POLBLIMK1LIMK2 | |
| SCHEMBL11025715 | 0.85 | POLB (0.78) | KMT2AMEN1POLBTCF4CTNNB1 | |
| SCHEMBL22653513 | 0.85 | POLB (0.65) | KMT2AMEN1POLBTCF4CTNNB1 | |
| SCHEMBL259382 | 0.84 | CA12 (0.66) | KMT2AMEN1LIMK1LIMK2MAPT | |
| SCHEMBL31681311 | 0.84 | CA12 (0.66) | KMT2AMEN1LIMK1LIMK2MAPT | |
| SCHEMBL3701951 | 0.84 | CA12 (0.71) | KMT2AMEN1MAPK1TCF4CTNNB1 | |
| SCHEMBL1592806 | 0.83 | LMNA (0.60) | KMT2AMEN1LIMK1LIMK2MAPK1 | |
| SCHEMBL13765762 | 0.83 | KDM4E (0.67) | KMT2AMEN1POLBGFERCA12 | |
| SCHEMBL3715141 | 0.82 | CA12 (0.75) | KMT2AMEN1POLBGFERMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275539-A1 | APYRASE INHIBITORS | TEXAS CROP SCIENCE INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3626240-A1 | PROCESS OF PREPARATION OF A N-ARYL BENZYL SULFONAMIDE SUBSTITUTED WITH AN AMIDO GROUP | StemSynergy Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9416101-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901306-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | STEMSYNERGY THERAPEUTICS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2403499-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | Stemsynergy Therapeutics, Inc (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101964-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010101964-A2 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | STEMSYNERGY THERAPEUTICS, INC (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834446-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
| US-10975067-B2 | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
| US-20230110928-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
| US-20150051177-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
| US-11512081-B2 | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
| US-20250275539-A1 | APYRASE INHIBITORS | APEH, GBA3, PON1 | KMT2A 1992/4885MEN1 4096/4885POLB 3118/4885 |
| US-20120046250-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
| US-20210188835-A1 | METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL | WNT3A, WNT1, WNT3 | KMT2A 3839/4885MEN1 4226/4885POLB 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.